ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Samsung Biologics to make coronavirus antibody drug for US startup

Treatment set for clinical trials and mass production next year

Once the treatment is approved by health authorities, Samsung Biologics will shift to mass production next year. (Photo courtesy of the company)
KOTARO HOSOKAWA, Nikkei staff writer | South Korea

SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.

Read Next

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close